Skip to main content
main-content
Top

11-15-2017 | Neuropathy | News

Spinal cord stimulation efficacy sustained in patients with diabetic polyneuropathy

medwireNews: Patients with painful diabetic polyneuropathy continue to experience pain relief in the lower extremities for at least 5 years of spinal cord stimulation (SCS), suggest study findings.

The researchers found that SCS was successful in 86% of 36 patients 1 year after receiving a permanent implant and in 55% of 22 patients after 5 years, and survival analysis estimated that 80% of patients still used their SCS device after 5 years.

“Because SCS treatment is maintained over at least 5 years in patients with [painful diabetic polyneuropathy] and >50% of patients still use their initial SCS device after 5 years, SCS can be considered a cost-effective long-term treatment modality in patients with [painful diabetic polyneuropathy],” says the team.

Treatment success was based on achieving at least a 50% decrease in day or night numerical rating scale (NRS) pain score or a Patient’s Global Impression of Change (PGIC) score of 6 or above (much improved or very much improved).

Specifically, at 5 years, average NRS scores had decreased from 6.7 at baseline to 4.3 during the day and 4.6 during the night, and 36% and 32% of patients had achieved at least a 50% reduction in day and night scores, respectively.

PGIC improvement for pain and sleep was seen in a corresponding 50% and 32% of patients after 5 years.

Maarten van Beek (Maastricht University Medical Center, the Netherlands) and colleagues note in Diabetes Care that no associations were observed between baseline factors and SCS success, but a higher baseline Michigan Diabetic Neuropathy Score (MDNS) was significantly associated with SCS failure, increasing the risk for subsequent removal of the system 3.9-fold.

The researchers stress, however, that despite this association, 40% of patients with the highest MDNS still used their SCS device after 5 years.

“Therefore, patients with [painful diabetic polyneuropathy] with a high mean MDNS should not be deprived of SCS treatment,” they say.

“However, the results can help to inform patients with [painful diabetic polyneuropathy] who are seeking SCS treatment.”

Conversely, there was also a significant, albeit modest, association between higher NRS scores at night and a reduced risk for treatment failure, which van Beek and colleagues attribute to “the therapeutic window for SCS being smaller with a lower baseline pain score.”

By Lucy Piper

medwireNews is an independent medical news service provided by Springer Healthcare. © 2017 Springer Healthcare part of the Springer Nature group

Related topics

CME-accredited GLP-1RAs webcast

Learn more about GLP-1RAs with John Wilding, Julie Lovshin and Kamlesh Khunti

CME-accredited GLP-1RAs webcast on real-world data

Led by Melanie Davies, Stewart Harris & Takashi Kadowaki, this on-demand webcast focuses on treatment with GLP-1RAs, based on real-world data, and the emerging landscape of GLP-1RAs in the context of approved guidelines.

Image Credits